WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 413151
CAS#: 85721-05-7 (acetate)
Description: Zuclopenthixol acetate is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.
MedKoo Cat#: 413151
Name: Zuclopenthixol acetate
CAS#: 85721-05-7 (acetate)
Chemical Formula: C24H29ClN2O2S
Exact Mass:
Molecular Weight: 445.02
Elemental Analysis: C, 64.78; H, 6.57; Cl, 7.97; N, 6.30; O, 7.19; S, 7.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 53772-83-1 (free base) 58045-23-1 (HCl) 85721-05-7 (acetate) 64053-00-5 (decanoate)
Synonym: Zuclopenthixol acetate; EINECS 288-415-5; UNII-349S2ZHF05
IUPAC/Chemical Name: (Z)-4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethyl acetate
InChi Key: DFUPOTHAXAAUMS-ZTQBIIPRSA-N
InChi Code: InChI=1S/C20H21ClN2S.C4H8O2/c21-15-7-8-20-18(14-15)16(17-4-1-2-6-19(17)24-20)5-3-11-23-12-9-22-10-13-23;1-3-6-4(2)5/h1-2,4-8,14,22H,3,9-13H2;3H2,1-2H3/b16-5-;
SMILES Code: ClC1=CC(/C2=C\CCN3CCNCC3)=C(SC4=C2C=CC=C4)C=C1.CC(OCC)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 445.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Jayakody K, Gibson RC, Kumar A, Gunadasa S.
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD000525. doi: 10.1002/14651858.CD000525.pub3.
PMID: 22513898 Free PMC article. Review.
2. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.
Gibson RC, Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2004;(3):CD000525. doi:
3. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2001;(3):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 11686965 Updated. Review.
4. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses.
Fenton M, Coutinho ES, Campbell C.
Cochrane Database Syst Rev. 2000;(2):CD000525. doi: 10.1002/14651858.CD000525.
PMID: 10796549 Updated. Review.
5. Zuclopenthixol versus placebo for schizophrenia.
Lacey M, Jayaram MB.
Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi:
6. Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism.
Conca A, Bertsch E, Küng A, Waschgler R, Hrubos W, König P, Hansen M.
Eur Psychiatry. 2003 Feb;18(1):28-31. doi: 10.1016/s0924-9338(02)00008-1.
PMID: 12648893 Clinical Trial.
7. Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis.
Laurier C, Kennedy W, Lachaine J, Gariepy L, Tessier G.
Clin Ther. 1997 Mar-Apr;19(2):316-29. doi: 10.1016/s0149-2918(97)80120-8.
PMID: 9152570
8. Zuclopenthixol acetate in psychiatric emergencies: looking for evidence from clinical trials.
Coutinho E, Fenton M, Adams C, Campbell C.
Schizophr Res. 2000 Dec 15;46(2-3):111-8. doi: 10.1016/s0920-9964(99)00226-1.
PMID: 11120423
9. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, Pedersen V, Elgen K, Brekke B, Fredslund-Andersen K, et al.
Acta Psychiatr Scand. 1993 Jan;87(1):48-58. doi: 10.1111/j.1600-0447.1993.tb03329.x.
PMID: 8093824 Clinical Trial.
10. Zuclopenthixol acetate (Clopixol Acuphase) for rapid sedation.
Malhi GS, Holloway F, Taylor D.
Int J Psychiatry Clin Pract. 1999;3(2):135-6. doi: 10.3109/13651509909024774.
PMID: 24941096
